This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Age range
18 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Baseline Demographics
Timeframe: Baseline
Height
Timeframe: Baseline
Weight
Timeframe: Baseline
Blood Pressure
Timeframe: Baseline
Number and Percentage of Patients by Clinical Characteristic
Timeframe: Baseline
Duration of Antibiotic Prophylaxis
Timeframe: Baseline, Months 3, 6, 9, 12, 18, 24, 30, and 36
Number of Hospitalizations due to Severe Infection Before Iptacopan Initiation
Timeframe: Baseline
Age at C3G Diagnosis
Timeframe: Baseline
Number and Percentage of Patients by Clinical Features at First C3G Diagnosis
Timeframe: Baseline
Age at Last Kidney Transplantation Before Iptacopan Initiation
Timeframe: Baseline
Number of Kidney Transplants Before Iptacopan Initiation
Timeframe: Baseline
Number and Percentage of Patients by Clinical Features of Last Kidney Transplant Before Iptacopan Initiation
Timeframe: Baseline
Duration of Cold Ischemia for the Last Kidney Transplant Before Iptacopan Initiation
Timeframe: Baseline
Post-Kidney Transplant Estimated Glomerular Filtration Rate (eGFR)
Timeframe: Baseline
Number and Percentage of Patients by Type of Biopsy Performed to Confirm Recurrence of C3G After Kidney Transplant
Timeframe: Baseline
Duration Between Last Kidney Transplant and Biopsy Confirmed C3G Recurrence
Timeframe: Baseline
eGFR at Last Post-transplant C3G Recurrence
Timeframe: Baseline
Serum Albumin Concentration at Last Post-transplant C3G Recurrence
Timeframe: Baseline
Urine Protein-Creatine Ratio (UPCR) From First-Morning Void (FMV) at Last Post-transplant C3G Recurrence
Timeframe: Baseline
Proteinuria-24h at Last Post-transplant C3G Recurrence
Timeframe: Baseline
Serum Complement Component 3 (C3) Concentration at Last Post-transplant C3G Recurrence
Timeframe: Baseline